Social pharmacology: Conceptual remarks

Drug Information Journal

Volumn 38, Issue 4, 2004, Pages 321-329

  Alloza, José Luis ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Drug development; Drug surveillance; Postmarketing; Social pharmacology

Indexed keywords

DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; POLICY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RESEARCH; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL PHARMACOLOGY; SOCIOLOGY;

EID: 8644290266     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150403800403     Document Type: Review

References (70)

1. Lennard HL. A proposed program of research in sociopharmacology. In: Leiderman PH, Shapiro D, eds. Psychobiological Approaches to Social Behavior. Stanford, CA: Stanford University Press; 1964:127-137.
2. Barchas PR, Barchas JD. Sociopharmacology. In: Barchas JD, et al., eds. Psychopharmacology: From Theory to Practice. New York, NY: Oxford University Press; 1977:80-87.
3. McGuire MT, Raleigh MJ, Brammer GL. Sociopharmacology. Ann Rev Pharmacol Toxicol. 1982;22:643-661.
4. Blum K, Briggs AH, Cull JG. Holism: A social pharmacological approach to drug-seeking behavior. J Psychoactive Drugs. 1981:13;369-71.
5. Venulet J. Aspects of social pharmacology. In: Jucker J, ed. Progress in Drug Research. Basel and Stuttgart; Bikhäuser Verlag; 1978;22:10-25.
6. Venulet J. Towards social pharmacology. In Alloza JL, ed. Clinical and Social Pharmacology. Postmarketing Period. Aulendorf, Germany: Editio Cantor; 1985:129-139.
7. Alloza JL, ed. Clinical and Social Pharmacology. Postmarketing Period. Aulendorf, Germany: Editio Cantor; 1985.
8. Mant D. Can randomized trials inform critical decisions about individual patients? Lancet. 1999;353:743-745.
9. Lasagna L. Post-marketing surveillance. Triangle. 1980;19:107-111.
10. Experimental Technology Incentives Program. The Experiment in Post-Marketing Surveillance of Prescription Drugs: An Initial Status Report. Washington DC: National Bureau of Standards; 1982.
11. Weis OF, Sriwatanakul K, Alloza JL, Weintraub M, Lasagna L. Attitudes of patients, house staff, and nurses toward postoperative pain. Anesthesia Analgesia. 1983;62:70-74.
12. Alloza JL. Epidemiological drug surveys in the ambulatory care environment. In: Alloza JL, ed. Clinical and Social Pharmacology. Postmarketing Period. Aulendorf, Germany: Editio Cantor; 1985;38-56.
13. Leape LL. Reporting of adverse events. N Engl J Med. 2002;347:1633-1638.
14. Gurwith JH, Field JS, Harrold LR, Rothshild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Klelleher M, Baates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
15. Lasagna L. A plea for the "naturalistic" study of medicines. Eur J Clin Pharmacol. 1974;7:153-154.
16. Alloza JL. A naturalistic study on post-operative acute pain: comparison between two standard narcotic analgesics (morphine and meperidine). (Estudio "natural" sobre el dolor postoperatorio: Una comparación entre dos analgésicos narcoticos estándar.) Pain. (Dolor.) 1987;2:55-61.
17. Lasagna L. Phase IV: the opportunity and the challenge. In: Burley D, Haward C, Mullinger B, ed. The Focus for Pharmaceutical Knowledge. The Proceedings of the Sixth International Meeting of Pharmaceutical Physicians. Houndmils, U.K.: MacMillan Press Ltd.; 1988:115-118.
18. Temple RJ, Jones JK, Crout JR. Adverse effects of newly marketed drugs. N Eng J Med. 1979;300:1046-1047.
19. Alloza JL. Opiophobia and cancer pain. (Letter to the Editor). Lancet. 1993;341:1474-1475.
20. Rucker TD. Drug-utilization review: Moving toward an effective and safe model. In: Morgan JP, Kagan DC, ed. Society and Medication: Conflicting Signals for Prescribers and Patients. Lexington, MA: Lexington Books; 1983:25-51.
21. Rucker TD. Drug utilization review: Guidelines for program development. In: Alloza JL, ed. Clinical and Social Pharmacology: Postmarketing Period. Aulendorf, Germany: Editio Cantor; 1985:57-65.
22. Sriwatanakul K, Weis OF, Alloza JL, Kelvie W, Weintraub M, Lasagna L. Analysis of narcotic analgesic usage in the treatment of postoperative pain. JAMA. 1983;250:926-929.
23. Weintraub M. Intelligent noncompliance with special emphasis on the elderly. Contemp Pharm Pract. 1981;4:8-11.
24. Haynes RB, McDonald HP, Garg AX. Helping patients to follow prescribed treatment. JAMA. 2002;288:2880-2883.
25. Prescribing anomalies in Europe. Scrip. 1995;1995:7
26. Rucker TD. The formulary process at it relates to drug utilization review. P & T. 1992;17/4:646-657.
27. Nash DB, Catalano ML, Wordell CJ. The formulary decision-making process in a US academic medical center. PharmacoEcon. 1993;3:22-35.
28. Mashford ML. Drug information and therapeutic guidelines: A second opinion before prescribing. In: Alloza JL, ed. Communication in Health Care: Drug Information. III International Medical Pharmaceutical Meeting. Madrid, Spain: Madrid Doctors' Association; 1995:12-16.
29. Johnson KE, Hirshfeld EB, He ML, et al. Legal Implications of Practice Parameters. Chicago, IL: American Medical Association; 1990.
30. Torras J, Palés A, Güell JM, Alloza JL. Medical and economical analysis of the heparin antithrombotic prophylaxis versus nonprophylaxis in orthopaedics: A study of 920 traumatic patients. J Advances Orthopaedics, Surgery Labour Sport Rehab. (Avances de Traumatologia, Cirugía y Rehailitación Laboraly Deportiva.) 1985;15/2.
31. Tolpin HG. Cost-benefit assessment of pharmaceutical products. Drug Inf J. 1988;22:281-292.
32. Cooke J. The practical impact of pharmacoeconomics on institutional managers. PharmacoEcon. 1994;6:289-297.
33. Schrogie JJ. How decisions about health care are affected by outcomes research in USA. In: Alloza JL, ed. Second International Medical-Pharmaceutical Meeting. Changes in Health Care Delivery: Impact of Pharmaco-economics and Outcomes Measures. Spain, Madrid: Madrid Doctors' Association; 1994:9-11.
34. Schrogie JJ. Outcomes assessment. In: Johnson NE, Nash DB ed. The Role of Pharmacoeconomics in Outcomes Management. Chicago, IL: American Hospital Publishing Inc.; 1996:9-22.
35. Gibbong JH. Evaluation of the Oregon Medicaid Proposal. Washington, DC: U.S. Congress, Office of Technology Assessment; 1992.
36. Yan Q, Hunt CA. Preventing adverse drug events (ADEs): the role of computer information systems. Drug Inf J. 2000;34:1247-1260.
37. Marshall A. Laying the foundations for personalized medicines. Nature Biotech. 1997;15:954-957.
38. Maciá C, Paredes MB, Poncela MP, Alvarez MA, Castaño G, Venta R. Serum cortisol concentrations in acute non-critically ill patients measured in three periods of the day. (Concentración sérica de cortisol en tres franjas horarias en pacientes con enfermedad aguda no crítica.) Med Clín (Barc). 2001;117:254-256.
39. Rylance GW. Prescribing for infants and children. Br Med J. 1988;296:984-986.
40. Berd LA, Lipton HI, Bird JA. Characterization of geriatric drug-related hospital readmissions. Med Care. 1991;29:989-1003.
41. Davis NM, Cohen MR, ed. Medication Errors: Causes and Prevention. Philadelphia, PA: George F. Stickley Company; 1981.
42. Leape LL, Woods DD, Hatlie MJ, Kizer KW, Schroeder SA, Lundberg GD. Promoting patient safety by preventing medical error. JAMA. 1998;280:1444-1447.
43. Fink III JL. Compounding versus manufacturing in pharmacy practice: a regulatory challenge. J Pharm Pract. 1995;VIII/3:103-114.
44. Conlan MF. Compounding vs. manufacturing. Where is the line? Drug Topics. 1992; October: 46-52.
45. Herbal Prescriptions. The promises and pitfalls. Consumer Reports. 1999; March: 44-48.
46. Eisenberg D, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998;280:1569-1575.
47. Scheid V. The globalization of Chinese medicine. Lancet. 2000; (Supp. December 1999);354: siv10.
48. Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Int Med. 1997;127:61-69.
49. Chavez ML, Chapman RL. Homeopathy. Hospital Pharmacy. 1998;33:41-50.
50. Hróbjartsson A, Gotzche P. Is the placebo powerless? N Engl J Med. 2001;344:1594-602.
51. Hufford MR. Placebo effects, memory, and the value of real-time data in drug development. App Clin Trials. 2002; August:34-43.
52. Alloza J L, Alamo C, Espada M. Analysis of ambiguous terms widely used in the communication process among physicians, pharmacists and patients: A social pharmacology study. Methods Find Exp Clin Pharmacol. 2000;22:464.
53. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: What are Americans being sold? Lancet. 2001;358:1141-1146.
54. Alloza JL, Lasagna L. A comparison of drug product information in four national compendia. Clin Pharmacol Ther. 1983;33:269-277.
55. Johnson KW. Evaluation of drug product information: The example of the United States Pharmacopoeia. In: Alloza JL, ed. Third International Medical Pharmaceutical Meeting. Communication in Health Care: Drug Information. Madrid, Spain: Madrid Doctors' Association; 1995:17-22.
56. Shannon ME, Malecha SE, Cha AJ, Moody ML. Evaluation and critical appraisal of a random sample of drug information practice in United States academic and industry medical information centers. Drug Inf J. 2000;334:1133-1138.
57. Albert T. Written information for patients. Lancet 2000;356:434.
58. Bradbury J. UK panics over phthalates in babymilk formulae. Lancet. 1996;347:1541.
59. Moynihan R, Bero L, Ross-Degnan D, et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000;342:1645-1650.
60. McLellan F. "Like hunger, like thirst": patients, journals, and the Internet. Lancet. 1998:352 (suppl 11): sii 39-43.
61. Szalavitz M. Web sites and misinformation about illicit drugs. N Engl J Med. 2001;345:1710.
62. U.S. Food and Drug Administration. Buying Prescription Medicines Online: A Consumer Safety Guide. U.S. Food and Drug Administration; June 6, 2001. www.fda.gov/cder/drug/consumer/buy online/guide.htm.
63. Alloza JL, Alamo C, Espada M. Analysis of ambiguous terms widely used in the communication process among physicians, pharmacists and patients. Meth Find Exp Clin Pharmacol. 2000;22/6:27.
64. Drug promotion: stealth, wealth, and safety. Lancet. 1993;341:1507-1508.
65. Orellana C. German doctors links with drug firm investigated. Lancet. 2002;359:1039.
66. GSK mislead on Seroxat's effects. Scrip. March 21, 2003;2834:3.
67. Villanueva P, Peiró S, Libero J, Pereiró I. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003;361:27-32.
68. Alloza JL. The social pharmacology of "ask your doctor or pharmacist for advice." Concerns about self-medication with OTCs by the consumer and the pharmacist in the pharmacies in the Community of Madrid. Methods Find Exp Clin Pharmacol. 2002;24(Suppl.A):3:125.
69. Schiff GD, Rucker TD. Computerized prescribing. Building the electronic infrastructure for better medication usage. JAMA. 1998;279:1024-1029.
70. Alloza JL, Espada M, Alamo C, Cuenca E. Informed consent forms, comprehension and volunteering in a controlled clinical trial. Methods Find Exp Clin Pharmacol. 1996;18 (Suppl.B):117.